LIMINATUS PHARMA, INC. Other Receivable After Allowance For Credit Loss Noncurrent
LIMINATUS PHARMA, INC. (LIMN) had Other Receivable After Allowance For Credit Loss Noncurrent of $126.28 thousand as of 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Notes
us-gaap:OtherReceivableAfterAllowanceForCreditLossNoncurrent · last filed 2026-06-24
- 2025-09-30: Other Receivable After Allowance For Credit Loss Noncurrent $126.28K.
- 2025-06-30: Other Receivable After Allowance For Credit Loss Noncurrent $126.28K.
- 2024-12-31: Other Receivable After Allowance For Credit Loss Noncurrent $126.28K.
| Period end | Other Receivable After Allowance For Credit Loss Noncurrent |
|---|---|
| 2025-09-30 | $126.28K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $126.28K 10-Q · filed 2025-10-06 |
| 2024-12-31 | $126.28K S-1 · filed 2026-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |